Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Christina Annette Bjerre1, Jeanette Dupont Rønlev2, Ann Søegaard Knop1,3

  • 1Afdeling for Kræftbehandling, Københavns Universitetshospital - Rigshospitalet.

Ugeskrift for Laeger
|March 27, 2024
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Outcomes for patients with high-risk ER-positive, HER2-negative early-stage breast cancer: a Danish real-world study.

Acta oncologica (Stockholm, Sweden)·2025
Same author

Real-world efficacy of tucatinib in Danish human epidermal growth factor receptor 2-positive metastatic breast cancer.

Danish medical journal·2025
Same author

A direct comparison of classical oral Navelbine vs metronomic Navelbine in metastatic breast cancer: results from the Danish Breast Cancer Group's (DBCG) NAME-trial.

Breast cancer research and treatment·2025
Same author

Chronic chemotherapy-induced peripheral neuropathy and pain following paclitaxel versus docetaxel in breast cancer survivors: A cross-sectional study.

Breast (Edinburgh, Scotland)·2025
Same author

Real-world effectiveness of CDK 4/6 inhibitors in estrogen-positive metastatic breast cancer.

BJC reports·2024
Same author

Ugeskrift for laeger·2024

Adjuvant and neoadjuvant therapies for early breast cancer significantly lower relapse risk and mortality. Treatment selection is individualized using risk models and multidisciplinary review for optimal patient benefit.

Area of Science:

  • Oncology
  • Clinical Medicine

Background:

  • Adjuvant and neoadjuvant therapies are crucial for early breast cancer, aiming to reduce relapse and mortality.
  • A wide array of treatment modalities are available, including chemotherapy, endocrine therapy, HER2-targeted agents, and novel agents like CDK4/6 and PARP inhibitors.

Approach:

  • Multidisciplinary breast cancer tumor boards review all cases.
  • Individualized risk stratification models are employed to optimize the risk-benefit ratio for each patient.
  • Shared decision-making is integral to the (neo)adjuvant therapy process.

Key Points:

  • Treatment decisions are personalized based on risk stratification.
  • Multidisciplinary team review ensures comprehensive case evaluation.
  • Patient involvement through shared decision-making is emphasized.

Related Experiment Videos

Conclusions:

  • Current strategies effectively reduce early breast cancer recurrence and mortality.
  • Personalized treatment approaches guided by risk assessment and multidisciplinary input are standard practice.
  • Danish guidelines provide a framework for evidence-based breast cancer treatment.